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Immune escape and tolerance in the tumor microenvironment are closely
involved in tumor progression, and are caused by T-cell exhaustion and mediated
by the inhibitory signaling of immune checkpoint molecules including pro-
grammed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell
immunoglobulin and mucin domaincontaining molecule-3. In the present study,
we investigated the expression of the PD-1 ligand 1 (PD-L1) in a lymphoma
microenvironment using paraffin-embedded tissue samples, and subsequently
studied the detailed mechanism of upregulation of PD-L1 on macrophages using
cultured human macrophages and lymphoma cell lines. We found that macro-
phages in lymphoma tissues of almost all cases of adult T-cell leukemia/lym-
phoma (ATLL), follicular lymphoma and diffuse large B-cell lymphoma expressed
PD-L1. Cell culture studies showed that the conditioned medium of ATL-T and
SLVL cell lines induced increased expression of PD-L1/2 on macrophages, and that
this PD-L1/2 overexpression was dependent on activation of signal transducer
and activator of transcription 3 (Stat3). In vitro studies including cytokine array
analysis showed that IL-27 (heterodimer of p28 and EBI3) induced overexpression
of PD-L1/2 on macrophages via Stat3 activation. Because lymphoma cell lines pro-
duced IL-27B (EBI3) but not IL-27p28, it was proposed that the IL-27p28 derived
from macrophages and the IL-27B (EBI3) derived from lymphoma cells formed an
IL-27 (heterodimer) that induced PD-L1/2 overexpression. Although the signifi-
cance of PD-L1/2 expressions on macrophages in lymphoma progression has
never been clarified, an IL-27-Stat3 axis might be a target for immunotherapy for
lymphoma patients.
R ecent studies have shown the significant involvement ofmacrophages in tumor progression in several kinds of
human malignant tumors.(1–4) In addition, there are numerous
research articles that describe the protumor functions of macro-
phages that have infiltrated into the microenvironment of
hematological malignancies such as leukemia/lymphoma.(5)
Macrophages infiltrating into the tumor microenvironment are
referred to as tumor-associated macrophages (TAM). TAM are
considered to be related to tumor progression through their
association with tumor cell survival, angiogenesis, metastasis,
invasion and immune suppression.(6)
Immune escape and tolerance in the tumor microenviron-
ment are closely involved in tumor progression, and are caused
by T-cell exhaustion and mediated by inhibitory signals due to
the activation of immune checkpoint molecules, including pro-
grammed death-1 (PD-1), cytotoxic T-lymphocyte associated
protein 4 (CTLA-4) and T cell immunoglobulin and mucin
domain-containing-3 (TIM3).(7,8) The PD-1 ligand 1 (PD-L1,
also known as B7-H1) is known to be widely expressed by
leukocytes and tumor cells, whereas PD-L2 (also known as
B7-DC) is expressed mainly by dendritic cells and
macrophages.(9) Anti-tumor responses after blocking mono-
clonal antibodies against PD-1 signals are currently being
reported in some kinds of malignant tumors, including lym-
phoma, and, therefore, blocking of immune checkpoint mole-
cules is considered to be a new anti-tumor therapy.(10–12) A
number of research studies have focused on PD-L1 expression
in stromal cells in the tumor microenvironment;(13,14) however,
only a few studies have investigated PD-L1/2 expression on
myeloid cells in human malignant tumors.(15,16)
In the present study, we demonstrated PD-L1/2 expressions
on TAM in almost all malignant lymphoma cases that are
frequently seen in Japan, including adult T cell leukemia/lym-
phoma (ATLL), follicular lymphoma (FL) and diffuse large
B-cell lymphoma (DLBCL). We then investigated the detailed
mechanisms of PD-L1/2 overexpression on TAM using human
monocyte-derived macrophages and some lymphoma cell lines.
Materials and Methods
Tissue samples. Paraffin-embedded tumor samples from
lymph node biopsies diagnosed as ATLL (16 cases), FL
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(25 cases) and DLBCL (56 cases) during 2005–2014 were
examined. Written informed consent was obtained from all
patients in accordance with protocols approved by the Kuma-
moto University Review Board.
Immunohistochemistry. Rabbit monoclonal antibody against
PD-L1 (clone E1L3N; Cell Signaling Technology, Danvers,
MA, USA) or PD-L2 (clone D7U8C; Cell Signaling Technol-
ogy), mouse monoclonal antibody against CD163 (clone 10D6;
Leica Biosystems, Wetziar, Germany), CD19 (Clone LE-
CD19, DAKO) or anti-IL-27B (Epstein–Barr virus induced 3,
EBI3; clone 15k8D10, Novus Biologicals, Minneapolis, MN,
USA), and rabbit polyclonal antibody against IL-27p28
(Abcam, Cambridge, UK) were used as primary antibodies for
immunostaining. Briefly, after samples were reacted with the
primary antibodies, they were incubated with HRP-labeled
goat anti-rabbit secondary antibodies (Nichirei, Tokyo, Japan).
Can Get Signal Solution (TOYOBO, Tokyo, Japan) was used
to dilute the antibodies to enhance the immunoreaction of
PD-L1 and PD-L2. Reactions were visualized using the
diaminobenzidine substrate system (Nichirei). For double
immunostaining, goat anti-mouse antibody labeled with Alexa
488 and goat anti-rabbit antibody labeled with Alexa 546
(ThermoFisher, Waltham, MA, USA) were used as secondary
antibody. Two pathologists (HH and YK), who were blinded
to information about the samples, evaluated the immunostain-
ing of PD-L1/2 and CD163.
Cell lines. The human ATLL cell lines (ATN-1, ATL-T,
MT-1), T-cell lymphoma cell lines without HTLV-1 infection
(SKW-3, MOLT-4), EBV-infected B-cell lines (103-LCL, 141-
LCL) and B-cell lymphoma cell lines (DAUDI, TL-1, NALM,
Raji, SLVL, BALL1) were maintained in RPMI supplemented
with 10% FBS. ATL-T and MT-1 were previously established
by Taylor and Matsuoka,(17) and other cell lines were pur-
chased from RIKEN Cell Bank (Wako, Tokyo, Japan). The
mycoplasma test was performed using a PCR Detection Kit
(Takara Bio, Otsu, Japan).
Macrophage culture. Peripheral blood mononuclear cells
were obtained from healthy volunteer donors, who had all pro-
vided written informed consent for the use of their cells in
accordance with the study protocols approved by the Kuma-
moto University Hospital Review Board (No. 1169). CD14+
monocytes were isolated using CD14-microbeads (Miltenyi
Biotec, Bergisch Gladbach, Germany). These monocytes were
plated in 12-well culture plates (2 9 105 cells/well, UpCELL;
CellSeed, Tokyo, Japan) and were cultured in 2% human
serum, 1 ng/mL granulocyte macrophage-colony stimulating
factor (GM-CSF; Wako), and 50 ng/mL macrophage-colony
stimulating factor (M-CSF; Wako) for 7 days to induce differ-
entiated macrophages. In some experiments, the Stat3 inhibitor
WP1066 dissolved in DMSO was added at a final concentra-
tion of 20 lM. IL-27 (heterodimer of p28 subunit and EBI3)
was obtained from BioLegend (San Diego, CA, USA).
Flow cytometry. Cells were detached using cell dissociation
buffer (Thermo Fisher Scientific, Waltham, MA, USA), and
stained using PE-labeled anti-PD-L1 antibody and APC-labeled
anti-PD-L2 antibody (BioLegend) with Fc receptor blocking solu-
tion (BioLegend). Isotype-matched control antibodies were also
obtained from BioLegend. The stained cell samples were analyzed
on a FACSverse (Becton Dickinson, Franklin Lake, NJ, USA)
flow cytometer with FACSuite (Becton Dickinson) software.
Real-time quantitative PCR. Total RNA was isolated using
RNAiso Plus (Takara Bio). RNA was reverse-transcribed by
means of a PrimeScript RT Reagent Kit (Takara Bio Inc.).
Quantitative real-time PCR was performed using TaqMan
polymerase with SYBR Green Fluorescence (Takara Bio) and
an ABI PRISM 7300 Sequence Detector (Applied Biosystems,
Foster City, CA, USA). The primers used were as follows: for
PD-L1, sense 50-GAC.CAG.CAC.ACT.GAG.AAT.CAA.CAC-
30, antisense 50-TTG.GAG.GAT.GTG.CCA.GAG.GTA.G0; for
PD-L2, sense 50-GAA.ACT.TCA.GCT.GTG.TGT.TCT.GG-30,
antisense 50-GCA.GAA.GGG.GAT.GAA.AAT.GTG-30; for IL-
27B (EBI3), sense 50-CTC.CCT.ACG.TGC.TCA.ATG.TCA.C-
30, antisense 50-GGC.TTG.ATG.ATG.TGC.TCT.GTT.ATG-30;




b-actin, sense 50-ATT.CCT.ATG.TGG.GCG.ACG.AG-30, anti-
sense 50-AAG.GTG.TGG.TGC.CAG.ATT.TTC-30.
Western blot analysis. Cells were lysed in ice-cold lysis buf-
fer (50 mM Tris pH 8.0, 1 mM EDTA, 150 mM NaCl, 1%
NP-40) with a phosphatase inhibitor cocktail (R&D, Min-
neapolis, MN, USA) and a protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA). PVDF membrane was reacted
with antibodies against Ij-Ba, pStat3, Stat3 and PD-L1 (all
antibodies were from Cell Signaling) or with anti- b-actin anti-
bodies (Santa Cruz Biotechnology, Dallas, TX, USA). HRP-
Goat anti-mouse or rabbit IgG (Invitrogen, Camarillo, CA,
USA) was used as the second antibody. Immunoreactive bands
were visualized using the Pierce Western Blotting Substrate
Plus Kit (Thermo Scientific, Rockford, IL, USA) and Image-
Quant LAS-4000 mini (Fuji Film, Tokyo, Japan).
Cytokine array of culture supernatant. The cytokine array kit
was purchased from R&D Systems (Human XL Cytokine
Array Kit #ARY022, Minneapolis, MN, USA). The signal den-
sities of spots were evaluated using Image J software (https://
imagej.nih.gov/ij/).
Statistics. Statistical analysis of in vitro and in vivo data
was carried out using JMP10 (SAS Institute, Chicago, IL,
USA) and StatMate III (ATOMS, Tokyo, Japan). A
P-value < 0.05 was considered to be statistically significant.
The v2-test, Mann–Whitney U-test, and paired t-test were
used for statistical analysis. All data used in the cell-culture
study were representative of at least three independent
experiments.
Results
PD-L1/2 expressions were detected on tumor-associated macro-
phages in almost all cases. Immunostaining for PD-L1 was per-
formed on paraffin sections of the tumors of 25, 56 and 15
cases of FL, DLBCL and ATLL, respectively. Characteristics
of the patients are shown in Table 1. The lymphoma cells of
1, 2 and 1 cases of FL, DLBCL and ATLL, respectively,
stained positive for PD-L1 (Table 2); however, we found that
in almost all cases in which the lymphoma cells were negative
for PD-L1 the TAM stained positive for PD-L1 (Fig. 1a).
Table 1. Characteristics of patients
FL DLBCL ATLL
Age (mean) 36–81 (56) 35–87 (61) 31–86 (67)
M/F 14/11 30/26 8/8
Grade 1/2/3 9/12/4 — —
GBC/Non-GBC — 19/37 —
ATLL, adult T cell leukemia/lymphoma; DLBCL, diffuse large B-cell lym-
phoma; FL, follicular lymphoma.
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PD-L1 expression in TAM (Fig. 1b) and in lymphoma cells
(Fig. 1c,d) was confirmed by double-fluorescent immunostain-
ing. Next, the same lymphoma case set was immunostained for
PD-L2. PD-L2 expression on lymphoma cells was seen in 0, 2
and 0 cases in FL, DLBCL and ATLL, respectively (Fig. 1e,
Table 2). However, the staining intensity of PD-L2 on TAM
was too weak to evaluate adequately and we could, therefore,
not investigate PD-L2 expression on TAM in tissue sections
(Fig. 1e). Cases in which PD-L1 was positive for lymphoma
cells were different from cases in which PD-L2 was positive
for lymphoma cells. Four DLBCL cases in which lymphoma
cells were positive for either PD-L1 or PD-L2 belonged to the
non-GCB type (Table 2), and three of these patients died
within 2 years from diagnosis (data not shown).
PD-L1 and PD-L2 expression on macrophages was increased by
the conditioned medium of SLVL, MT-1 and ATL-T cell lines. Both
PD-L1 and PD-L2 are known to be expressed on macrophages.
We then tested if PD-L1 and PD-L2 expression on macro-
phages is changed by secreted factors from lymphoma cells
using human monocyte-derived macrophages. Culture super-
natants of B- and T-cell lymphoma cell lines were collected
and used as conditioned medium (CM). Macrophages were
stimulated with CM for 24 h following which PD-L1 and
PD-L2 expression on macrophages was evaluated using flow
Table 2. PD-L1/2 expression on lymphoma cells
Lymphoma cells
PD-L1 (negative/positive) PD-L2 (negative/positive)
FL
Grade 1 9/0 9/0
Grade 2 12/0 12/0





ATLL, adult T cell leukemia/lymphoma; DLBCL, diffuse large B-cell lym-
phoma; FL, follicular lymphoma; GCB, germinal center B-cell.
Fig. 1. PD-L1 expression in lymphoma tissues. (a)
Representative immunostaining of PD-L1 and
CD163 in DLBCL and ATLL is shown. Lymphoma
cells in patient (Pt.)5 and Pt.42 stained positive for
PD-L1, whereas tumor-associated macrophages
(TAM) in Pt.14 and Pt.37 stained positive for PD-L1.
(b) Double-fluorescent immunostaining of PD-L1
and CD163 in Pt.37 confirmed that TAM express PD-
L1. Scale bar: 25 lm. (c) Double-fluorescent
immunostaining of PD-L1/CD19 and PD-L1/CD163 is
shown. In DLBCL (Pt.42), CD19-positive lymphoma
cells stained positive for PD-L1. (d) In ATLL (Pt.5),
CD163-positive TAM and CD163-negative lymphoma
cells stained positive for PD-L1. Scale bar: 25 lm. (e)
PD-L2 positive signals were detected on TAM and
lymphoma cells in Pt.42 and Pt.18, respectively.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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Fig. 2. PD-L1/2 expression on cultured macrophages. (a) Scheme for testing the effect of the conditioned media (CM) from lymphoma cell lines
on PD-L1/2 expressions in macrophages. (b) Flow cytometric analysis of the effect of the CM of ATL-T on PDL-1 and PD-L2 expression. (c, d) His-
togram data of flow cytometric analysis of PD-L1 and PD-L2 expression on macrophages with or without stimulation with the CM of B-cell lym-
phoma cell lines (c) or T-cell lymphoma cell lines (d) (MFI, mean fluorescent intensity, n = 3 for each group). (e) The mRNA expression of PD-L1/2
in cells stimulated with the CM of the indicated cells lines was evaluated using RT-qPCR. *P-value < 0.05.
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Fig. 3. Stat3 activation and PD-L1/2 upregulation
on cultured macrophages. (a) Western blot analysis
of pStat3, Stat3 and IjBa expression in cell lysates
of cultured macrophages simulated with the
conditioned media (CM) of SLVL and ATL-T cells for
the indicated times. b-actin was analyzed as a
loading control. (b, c) The effect of the Stat3
inhibitor WP1066 on CM-induced overexpression of
PD-L1/2 on macrophages (Mac) was tested using
flow cytometry (MFI, mean fluorescent intensity;
n = 3 for each group). *P-value < 0.05.
Fig. 4. IL-27B (EBI3) and PD-L1/2 expressions on macrophages. (a) Cytokine array analysis showing the spots of CCL20 and IL-27B (EBI3) derived
from the conditioned media (CM) of the indicated cell lines. Spot intensity was evaluated using ImageJ software. (b) The mRNA expressions of
CCL20, IL-27 (EBI3), and IL-27p28 in cells lines and activated T cells were evaluated using RT-qPCR. (c) Western blot analysis of pStat3, Stat3, IjBa
and b-actin (control) expression in the cell lysates of cultured macrophages simulated with IL-27B (EBI3) or CCL20 for the indicated times. (d)
Macrophages were stimulated with the recombinant IL-27B (EBI3) or CCL20 protein for 24 h, following which PD-L1/2 expressions on macro-
phages was tested using flow cytometry (MFI, mean fluorescent intensity; n = 3 for each group). *P-value < 0.05.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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cytometry (Fig. 2a). The results showed that the CM of SLVL,
MT-1 and ATL-T cell lines induced significant upregulation of
PD-L1 and PD-L2 in macrophages (Fig. 2b–d). No significant
changes in PD-L1 or PD-L2 levels were induced by the CM of
other cell lines. Increased mRNA expression of PD-L1 and
PD-L2 in macrophages was also observed by stimulation with
the CM of SLVL and ATL-T cell lines (Fig. 2e).
Upregulation of PD-L1 and PD-L2 expression on macrophages
was mediated by Stat3 activation. NF-kB and Stat3 signals are
known to be related to PD-L1 and PL-L2 expression. We
therefore next tested the signal molecules activated in macro-
phages by the CM of the SLVL and ATL-T cell lines.
Although degradation of IjBa was not observed following
stimulation with CM, significant activation of Stat3 was
induced by the CM of ATL-T cells (Fig. 3a). The Stat3 inhibi-
tor WP1066 significantly abrogated the PD-L1 and PD-L2
overexpression induced by the CM of ATL-T cells (Fig. 3b,c).
Although Stat3 activation by the CM of SLVL cells was not
obvious, the Stat3 inhibitor WP1066 also significantly abro-
gated the PD-L1 and PD-L2 overexpression that was induced
in macrophages stimulated with the CM of SLVL cells
(Fig. 3b,c).
IL-27B (EBI3) derived from lymphoma cells was involved in PD-
L1 and PD-L2 expression on macrophages. We next investigated
what kinds of soluble molecules in CM were associated with
PD-L1 and PD-L2 overexpression on macrophages by using a
cytokine array kit containing a total of 204 spots (102 soluble
human proteins). Because PD-L1 and PD-L2 overexpression
was induced by the CM of SLVL and ATL-T cell lines but
was not induced by the CM of ATN-1 and BALL1 cell lines,
proteins that were detected at a high level in the CM of SLVL
and ATL-T cells and at a low level in the CM of ATN-1 and
BALL1 cell lines were selected for further analysis. As shown
in Figure 4(a) and Figure S1, CCL17, CCL20, IL-27B (EBI3),
sICAM-1, GM-CSF and G-CSF were included in this list.
Because CCL20 and IL-27B/EBI3 are known to link to NF-kB
and Stat3 signals, CCL20 and IL-27B (EBI3) were focused on
in further studies. The mRNA expression of CCL20 was sig-
nificantly higher in SLVL and ATL-T cells, whereas the high
mRNA expression of IL-27B (EBI3) was seen in SLVL, ATN-
Fig. 5. The IL-27 (heterodimer) induced greater overexpression of PD-L1/2 on macrophages than IL-27B (EB13). (a) Macrophages were stimu-
lated with the same concentration (20 ng/mL) of recombinant IL-27B (EBI3) or IL-27 (heterodimer) for 24 h, following which PD-L1/2 expression
on the macrophages was tested using flow cytometry (MFI, mean fluorescent intensity). The data of three donors are shown. The results were
statistically analyzed using a paired t-test. (b) Macrophages were stimulated with IL-27B (EBI3) or the conditioned medium (CM) of the indicated
cell lines for 24 h, following which the mRNA expression of IL-27p28 was analyzed using RT-qPCR. (c) Western blot analysis of pStat3, Stat3, IjBa
and b-actin (control) expression in cell lysates of cultured macrophages simulated with IL-27 (heterodimer) for the indicated times. (d) The effect
of the Stat3 inhibitor WP1066 on IL-27-induced overexpression of PD-L1/2 on macrophages was analyzed using flow cytometry (MFI, mean fluo-
rescent intensity, n = 3 for each group). *P-value < 0.05.
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1 and ATL-T cells (Fig. 4b). The degradation of IkBa, which
reflects NF-kB activation, was not influenced by either recom-
binant CCL20 or IL-27B (EBI3), whereas slight activation of
Stat3 was induced by IL-27B (EBI3) (Fig. 4c). PD-L1 and
PD-L2 overexpression on macrophages was significantly
upregulated by IL-27B (EBI3); however, PD-L1 and PD-L2
expression was not changed by CCL20 (Fig. 4d).
IL-27 (heterodimer of EBI3 and p28) induced greater upregula-
tion of PD-L1 and PD-L2 on macrophages than IL-27B (EB13). It is
well known that IL-27, which is a heterodimer of IL-27B
(EBI3) and IL-27p28, is more highly related to Stat3 activation
than IL-27B (EBI3), and, moreover, that IL-27p28 is preferen-
tially produced by myeloid cells, including macrophages.(18,19)
No mRNA expression of IL27p28 was observed in all lym-
phoma cell lines, as shown in Figure 4(b), whereas 141-LCL,
activated T cell and macrophages express mRNA of IL27p28.
We therefore considered that lymphoma cell-derived IL-27B
(EBI3) and macrophage-derived IL-27p28 might be coupled in
the lymphoma microenvironment, and that the subsequent
IL-27 heterodimer might then induce PD-L1 and PD-L2 over-
expression on TAM. Indeed, IL-27B (EBI3) and the CM of
ATL-T cells both induced increased IL-27p28 mRNA expres-
sion in macrophages compared to medium alone (Fig. 5a). As
shown in Figure 5(b), the IL-27 heterodimer did induce higher
PD-L1 and PD-L2 overexpression on macrophages than
IL-27B (EBI3) at the same concentration, and also induced
strong activation of Stat3 on macrophages (Fig. 5c). WP1066
significantly abrogated the PD-L1 and PD-L2 overexpression
on macrophages that was stimulated by the IL-27 heterodimer
(Fig. 5d).
IL-27B (EBI3) is expressed on lymphoma cells. We next exam-
ined the distribution of IL27B (EBI3) in tumor tissue by
immunostaining. The distribution of IL-27p28 could not be
examined because the anti-IL-27p28 antibody was not suitable
for immunostaining of paraffin sections. The staining intensity
was categorized into three groups (negative, score 0; weakly
positive, score 1; strongly positive, score 2) as shown in Fig-
ure 6(a). IL27B (EBI3) expression was observed on lymphoma
cells of 80% of ATLL and 91% of DLBCL cases. The num-
bers of weakly positive (score 1) cases were significantly
higher than the numbers of strongly positive (score 2) cases
(Fig. 6b).
IL-27 induced PD-L1 and PD-L2 expression on lymphoma cells.
As the final step, we evaluated PD-L1 protein expression in
lymphoma cell lines by means of western blot analysis and
PD-L1/2 mRNA expression using real-time quantitative PCR
(RT-qPCR). Western blot analysis of PD-L1 expression
showed strong expression of PD-L1 in ATL-T and SLVL cells
and weakly positive signals in 103-LCL, 141-LCL and ATN-1
cells (Fig. 7a). RT-qPCR analysis indicated a similar expres-
sion pattern of PD-L1/2 mRNA (Fig. 7b).
Discussion
In the present study, we demonstrated that TAM in malignant
lymphoma expressed PD-L1 and potentially express PD-L2.
The double immunofluorescent staining data indicated that
almost all of the PD-L1-positive stromal cells are CD163-posi-
tive TAM, and that no PD-L1 expression was seen on other
stromal cells such as endothelial cells and lymphocytes. Simi-
lar observations of the expression of PD-L1 by TAM were
reported in glioma and malignant lymphoma.(16,20) In the study
of glioma patients, circulating monocytes isolated from glioma
patients expressed higher levels of PD-L1 as compared with
monocytes in healthy donors, and IL-10 was suggested to be
involved in PD-L1 overexpression in monocytes and TAM.(20)
With regard to PD-L2, the staining intensity of PD-L2 was too
weak to evaluate the positive cells adequately in the present
study; however, the staining pattern of PD-L2 appeared to be
similar to that of PD-L1 and CD163. Based on the in vitro
study of the present article, TAM are considered to express
PD-L2 as well as PD-L1. The observed difference in the
Fig. 6. IL-27B (EBI3) expression on lymphoma cells. (a, b) The staining
intensity of IL-27B (EBI3) was classified into three groups (negative,
score 0; weakly positive, score 1; strongly positive, score 2). Scale bar:
20 lm.
Fig. 7. PD-L1/2 expressions on lymphoma cell lines.
(a) The protein expression of PD-L1 in lymphoma
cell lines was analyzed using western blot analysis.
b-actin was analyzed as a loading control. (b) The
mRNA expression of PD-L1/2 in lymphoma cell lines
was analyzed using real-time quantitative PCR.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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immunostaining of PD-L1 and PD-L2 is considered to be due
to the lower specificity of the anti-PD-L2 antibody that was
used in this study as compared with that of the anti-PD-L1
antibody. In support of this finding, as shown in Figure 7, the
anti-PD-L1 antibody was suitable for western blot analysis;
however, the anti-PD-L2 antibody was not useful for western
blot analysis.
Analysis of the effect of the CM from several lymphoma
cell lines on macrophages indicated that the CM from SLVL
and ATL-T cells strongly induced overexpression of PD-L1/2
on macrophages via Stat3 activation. PD-L1/2 expressions on
macrophages are known to be mediated by NF-jB and Stat3
activation;(21,22) however, NF-jB in macrophages was not
influenced by the CM of the lymphoma cells in the present
study. NF-jB activation in macrophages was also not induced
by CCL20, IL27B (EBI3) or the IL27 heterodimer. These find-
ings indicate the significance of the Stat3 pathway in PD-L1/2
overexpression on macrophages. Stat1 was also activated by
the CM from SLVL and ATL-T cells (unpublished data), and
PD-L1 expression has been shown to be regulated by Stat1 as
well as by Stat3 in some cancer cells.(23,24) IL-27 is also
known to activate the Stat1 pathway in addition to the Stat3
pathway.(18) Carbotti et al.(25) demonstrated that IL-27-induced
activation of Stat1 and Stat3 was involved in PD-L1 expres-
sion in cancer cells; however, they did not investigate which
signal pathway is more important for PD-L1 expression.
Because a specific chemical inhibitor against Stat1 is not com-
mercially available, we could not evaluate whether Stat1 or
Stat3 is more closely related to PD-L1/2 expression on macro-
phages in the present study. Some previous studies have shown
Stat3-dependent PD-L1 expression in myeloid cells and cancer
cells,(26–28) whereas Stat1-dependent PD-L1 expression was
reported in macrophages.(29) We are currently planning further
studies to address this problem, and, therefore, we did not pre-
sent the data regarding Stat1 in this article.
Important questions that remain to be answered are the sig-
nificance of PD-L1 expression in stromal cells and its role in
therapeutic responses as an immune checkpoint inhibitor. High
expression of PD-L1 in infiltrating macrophages and dendritic
cells correlated well with better clinical response of advanced
cancer patients to treatment with an anti-PD-L1 antibody.(30)
High PD-L1 expression in infiltrated immune cells also pre-
dicted better clinical response of advanced bladder cancer
patients to treatment with an anti-PD-L1 antibody, although it
was unclear if the PD-L1-positive cells were myeloid cells.(31)
An increased number of TAM expressing PD-L1 is associated
with an elevated number of infiltrating regulatory T cells in
ovarian cancer.(32) The function of PD-L1 on TAM has not yet
been elucidated. However, these findings indicate that TAM
are involved in immune suppression in the tumor microenvi-
ronment via a PD-L1-PD-1 axis.
In the present study, lymphoma cell-derived soluble factors
were also found to be involved in PD-L1/2 overexpression in
TAM via Stat3 activation, and IL-27B (EBI3) derived from
lymphoma cells was suggested to be involved in PD-L1/2
overexpression on TAM. However, Stat3 activation due to IL-
27B (EBI3) was significantly weaker than that due to the CM
of ATL-T, and, therefore, we considered that TAM-derived
IL-27p28 and lymphoma-derived IL-27 (EBI3) would form
IL-27 (heterodimer), which is known to be related to PD-L1
expression, as summarized in Figure S2. As expected,
IL-27p28 expression on macrophages was increased by stimu-
lation with IL-27B (EBI3) or the CM of ATL-T cells, and
IL-27 (heterodimer) induced strong activation of Stat3 on
macrophages as compared with that induced by IL-27 (EBI3).
In Figure 3, the expressions of PD-L1/2 were decreased by
WP1066, although Stat3 activation in macrophages stimulated
with CM of SLVL cells was not activated. We evaluated the
phosphorylation of Tyr 705 of Stat3 in the present study. Other
phosphorylation sites such as Ser727 are also known as a tar-
get for Stat3 inhibitor,(33) and this indicated that CM of SLVL
cells induced phosphorylation of other sites of Stat3.
In Figure 6, we found that IL-27B (EBI3) was expressed on
lymphoma cells in many cases. Strong IL-27B (EBI3) expres-
sion was observed in 7% and 10% of ATLL and DLBCL
cases, respectively; however, these cases are negative for PD-
L1/2. Cases with PD-L1/2-positive lymphoma cells showed
weak expression of IL-27B (EBI3), whereas the in vitro study
using lymphoma cell lines showed that IL-27B (EBI3) and
PD-L1/2 expressions were well correlated. Epigenetic changes
or differences of genome between primary cells and cell lines
might provide an explanation for this discrepancy.
In conclusion, PD-L1, and also probably PD-L2, were highly
expressed on TAM in almost all cases of lymphoma studied.
In vitro study suggested that Stat3 activation was closely
involved in PD-L1/2 overexpression on TAM. IL-27 was sug-
gested to be involved in Stat3 activation and PD-L1/2 overex-
pression. Although the significance of PD-L1/2 expressions on
macrophages in lymphoma progression and response to anti-
lymphoma therapy remains to be clarified, the IL-27-Stat3 axis
might be a target for immunotherapy for lymphoma patients.
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Fig. S2. Hypothesis of induction of PD-L1/2 expressions on tumor-associated macrophages (TAM).
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